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ABSTRACT
Objectives To estimate the loss of quality of life and cost
of treatment associated with genital warts seen in
sexual health clinics.
Methods A cross-sectional questionnaire study and
case note review of individuals with genital warts,
carried out in eight sexual health clinics in England and
Northern Ireland. Individuals with genital warts attending
the participating clinics were invited to take part in the
questionnaire study. 895 participants were recruited.
A separate sample of 370 participants who had attended
a participating clinic with a first visit for a first or
recurrent episode of genital warts between April and
June 2007 was included in the case note review. Quality
of life was measured using the EQ-5D questionnaire and
the cost of an episode of care was derived from the case
note review.
Results The weighted mean EQ-5D index score was
0.87 (95% CI 0.85 to 0.89). The weighted mean disutility
was 0.056 (95% CI 0.038 to 0.074). The estimated mean
loss of quality-adjusted life-years associated with an
episode of genital warts was 0.018 (95% CI 0.0079 to
0.031), equivalent to 6.6 days of healthy life lost per
episode. The weighted mean cost per episode of care
was £94 (95% CI £84 to £104), not including the cost of
a sexually transmitted infection screen.
Conclusions Genital warts have a substantial impact on
the health service and the individual. This information can
be utilised for economic evaluation of human
papillomavirus vaccination.
Human papillomavirus (HPV) vaccination is avail-
able free at the point of delivery through the
national vaccination programme in England, which
offers school-based HPV vaccination routinely to
12e13-year-old girls. Scotland, Wales and Northern
Ireland offer equivalent vaccination programmes.
Two vaccines are licensed for use in the UK,
a bivalent (Cervarix) and a quadrivalent (Gardasil).
The choice of vaccine to include in the national
programme was made following a competitive
tendering process1 informed by an economic eval-
uation.2 Information about the impact of genital
warts was a key determinant of the relative cost
effectiveness of the two available HPV vaccines, as
whereas both vaccines protect against HPV 16 and
18, which cause the majority of cases of cervical
cancer,3 4 only the quadrivalent vaccine offers
protection against HPV 6 and 11,5 the cause of
most genital warts.6
The impact of genital warts on the health service
is substantial, with approximately 125 000 episodes
of genital warts diagnosed in sexual health clinics in
England in 2009.7 Treatment consists of clinic-
based ablative treatments, pharmaceutical thera-
pies administered by the patient at home, or
a combination of these approaches. Cases may
require repeated treatments before clearance of the
lesion(s), and recurrence rates following treatment
of between 10% and 40% have been reported in
clinical trials.8 The majority of cases in England are
treated in sexual health clinics, although some are
treated in primary care and a small proportion
require referral to hospital for surgical removal.9
The widespread use of the quadrivalent HPV
vaccine has been reported to have a large effect on
the incidence of genital warts.10e12 The potential
beneﬁts in terms of quality of life and costs
saved should be included when comparing cost
effectiveness of HPV vaccines and vaccination
strategies. The costs and quality of life loss from
a single centre study have previously been used in
economic evaluation of HPV vaccination.13 14 Given
remaining questions about the value of vaccination
against genital warts,1 15 16 we carried out a multi-
centre study to provide estimates of quality of life
loss and cost per episode of care for use in further
economic evaluations of HPV vaccination.
METHODS
The study was carried out in a convenience sample
of seven sexual health clinics in England
(Birmingham, Cambridge, Harrogate, Homerton
and the Mortimer Market Centre in London,
Shefﬁeld and York) and one in Northern Ireland
(Belfast). The sites were chosen to be a mix of
urban and semi-urban clinics and had varying sizes
of patient population. The Homerton clinic also
provided specialist laser treatment for severe cases
of warts referred from other centres.
The study was conducted in two parts: a ques-
tionnaire was used to collect information about
quality of life and consultation time, and a case
note review was used to collect costs of treatment
and the duration of an episode of care.
Questionnaire study
Patients aged 16 years or over attending the
participating centres during the recruitment period
with a current diagnosis of genital warts were
invited to complete a questionnaire during their
clinic visit, consisting of demographic and behav-
ioural questions and questions about the partici-
pant’s genital warts history. Data collection took
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place between August 2009 and February 2010. Each clinic
recruited for at least 3 months.
The questionnaire included the EQ-5D, which is a short,
standardised generic questionnaire to measure health-related
quality of life.17 The EQ-5D requires respondents to state
whether they have no, some, or extreme problems in relation to
ﬁve dimensions of their health (mobility, usual activities, self-
care, pain or discomfort and anxiety or depression). Combina-
tions of answers to these questions are mapped to health states
with index scores from 0 to 1 according to preference weights
applied from a general population sample.18 The EQ-5D also
includes a visual analogue scale (EQ-VAS), in which respondents
are asked to rate their current state of health on a scale of 0e100.
The attending staff members noted the consultation duration
and treatment provided on an accompanying questionnaire.
EQ-5D scores for each participant were compared with age
group and sex-matched average scores from the standard UK
reference population (UK population norms).19 Disutility was
deﬁned as the difference between the study population and UK
population norms on the EQ-5D index.
Time from onset until attendance was calculated for partici-
pants attending for a ﬁrst visit of the ﬁrst episode only, as it
appeared that participants with recurrent episodes often
reported the start of their ﬁrst episode, rather than the onset of
symptoms for the current one. Participants from the Homerton
clinic were excluded from this analysis due to the high propor-
tion of referrals from other sexually transmitted infection (STI)
clinics at this site.
Participants who gave consent for follow-up were sent
a second questionnaire 2 weeks after their baseline visit, either
by post or email.
Case note review
Sequential individuals attending for a ﬁrst visit of either a ﬁrst or
recurrent episode between April and June 2007 were selected for
the case note review. The data collection period ended on 31
August 2009; thus each patient had a minimum of 2 years of
potential follow-up time available. Each individual contributed
one episode of care (deﬁned as the period between the ﬁrst and
last clinic visit for that occurrence of warts).
Details of the treatments received and the staff members
involved at each visit of the study episode of genital warts were
collected. Costing was carried out from a health service
perspective. Unit costs for staff20 and treatments were applied to
estimate the cost per episode of care (table 1). Site-speciﬁc
average consultation times for genital warts collected prospec-
tively as part of the questionnaire study were used (see
supplementary technical appendix, available online only). All
costs were calculated as 2010 pounds sterling. No discount rate
was applied as the costs of genital warts treatment were
incurred within 12 months in 98% of cases. It is standard
practice to test patients attending sexual health services for
other STI including HIV.24 However, economic evaluations of
vaccination have not previously taken into account the potential
beneﬁts of such screens (ie, detection of an undiagnosed infec-
tion). Therefore costs per episode are presented here both with
and without the cost of an STI screen (£52.12 per person, esti-
mated from a previous study,23 comprising laboratory costs for
chlamydia and gonorrhoea nucleic acid ampliﬁcation tests,
syphilis and HIV tests).
Loss of quality-adjusted life-years
Quality of life was assumed to decrease linearly from the level of
the UK population norm to the level measured in the study
between noticing warts and the start of an episode of care, and
then remain at the measured level until the end of the episode of
care (at the last clinic visit for that wart episode). In the base
case, quality of life was assumed to remain at this level for the
duration of any prescription for home treatment (28 days)22
received at the last visit. When only clinic treatment had been
used at the last visit of the episode of care, quality of life was
assumed to remain constant for a recovery period, estimated
based on the opinion of the clinical investigators as 14e42 days,
depending on treatment. Previous studies have found that
quality of life can be affected after the clearance of warts,25 26
although reliable estimates for the duration of any continued
detriment are not available in the literature. In order to make
allowance for some continuing quality of life loss at the end of
the episode, quality of life was assumed to return to the UK
population norm linearly over 2 weeks. We varied our assump-
tions (by including or excluding the additional assumed
durations following the episode of care) in sensitivity analyses.
Sample size and statistical analysis
A target sample size of 230 was determined to be sufﬁcient to
detect a difference of 0.04 on the EQ-5D index between indi-
viduals recruited with genital warts and population controls. For
the case note review, we aimed to review 40 (20 male, 20 female)
case notes per site.
Sampling weights were applied to allow for differential
recruitment from each clinic and to standardise estimates to the
age and sex distribution of patients aged 16e64 years attending
sexual health clinics in England in 2009 with a diagnosis of
genital warts.27 In the case note review, observations from
patients receiving laser treatment were also weighted to prevent
overestimation of costs and duration associated with this
specialist treatment. Non-parametric tests of signiﬁcance were
used to compare quality of life and cost per episode of care
between centres and subgroups. Data on duration and disutility
were obtained from two different sources (the retrospective case
note review and the questionnaire survey). We combined the
two sets of data to construct a simulated dataset in order to
estimate mean quality-adjusted life-year (QALY) loss and CI.
Bootstrapped CI were estimated from repeated constructions of
the simulated dataset (see supplementary technical appendix,
available online only).
Table 1 Unit costs*
Item Cost per use Source
Podophyllotoxin cream £14.86 21
Podophyllotoxin solution £12.38 22
Imiquimod £51.32 21
Cryotherapy £4.27 Clinic costing
Trichloroacetic acid £0.32 Clinic costing
Podophyllin £0.02 21
EMLA cream £1.73 22
Hyfrecation £5.63 Clinic costing
Curettage £4.66 Clinic costing
Diode laser £143.50 Clinic costing
CO2 laser £125.49 Clinic costing
STI screeny £52.12 23
*Costs per use include equipment, consumables and pharmaceuticals
plus tax (17.5%) when applicable. A detailed breakdown of the items
included for each cost is provided in the supplementary technical
appendix (available online only).
yIncludes testing for chlamydia, gonorrhoea, syphilis and HIV.
CO2, carbon dioxide; EMLA, eutectic mixture of local anaesthetic; STI,
sexually transmitted infection.
Sex Transm Infect 2011;87:458e463. doi:10.1136/sextrans-2011-050073 459
Health services research
group.bmj.com on October 27, 2015 - Published by http://sti.bmj.com/Downloaded from 
Completion of the questionnaire was considered as consent
for participation in the questionnaire study. Consent was not
obtained from individuals in the case note review; data collection
was conducted by the local clinical team who sent anonymised
data to the central study coordinator for analysis. The study
was approved by the South Humber research ethics committee.
RESULTS
Questionnaire study
Eight hundred and ninety-ﬁve participants were recruited
into the questionnaire study (table 2). The majority (65%) of
participants were attending with a ﬁrst episode of genital warts
and 42% of participants attending with a ﬁrst episode of warts
had previously attended their general practitioner to seek advice
or treatment. The weighted mean time from the onset of lesions
to attendance was 111 days (table 3).
The weighted mean EQ-5D index score was 0.87, and the
weighted mean EQ-VAS score was 77 (table 3). The weighted
mean disutility was 0.056. Disutility was larger (indicating
a greater loss of quality of life) in women (0.063) than men
(0.043) (p<0.0001). No signiﬁcant difference was observed
between ﬁrst or recurrent episodes, but disutility did differ by
age group (p¼0.0001), with the highest loss of quality of life seen
in 16e19-year-old women and 35e44-year-old men (ﬁgure 1).
The majority of the detriment to quality of life was registered
on the pain and anxiety domains of the EQ-5D, with 37% of
participants indicating they had moderate or extreme problems
with anxiety or depression and 26% with pain or discomfort.
Four hundred and thirty-seven out of 895 participants
consented to follow-up, of which 142 (32%, 16% overall)
completed a follow-up questionnaire (68 men, 74 women).
The mean time between baseline and follow-up was 31 days.
Eighty-seven (61%) participants reported that they still had
warts at follow-up; 20% (17/84) of participants who still had
genital warts had improved EQ-5D index scores at follow-up, as
did 32% (17/53) of those whose warts had cleared, although the
difference between these groups was not statistically signiﬁcant
(p¼0.12).
Case note review
Three hundred and seventy participants were included in the
case note review (table 4). Patients in the review attended for
a mean of 2.5 visits per episode of care. After applying sampling
weights, an episode of care lasted for a mean of 36 days (95% CI
27 to 46) (table 3). The duration and number of visits was highly
skewed, with 55% of men and 45% of women attending for only
one visit.
The weighted mean cost per episode of care was £94 (95% CI
£84 to £104) excluding the STI screen (table 3). There was
signiﬁcant variation in cost per episode of care between
recruiting centres (p¼0.0004, excluding laser patients) with the
cost for non-laser patients ranging from £86 to £137 (ﬁgure 2).
The mean cost per episode of care for patients receiving laser
treatments was £588.
Table 2 Characteristics of participants in the questionnaire study
Male Female All
n[494 n[400 n[895
Age, years
Mean 30 25 28
Range (minemax) 17e60 16e73 16e73
Visit type
First 51% (245) 53% (204) 52% (449)
Follow-up 49% (232) 47% (183) 48% (415)
First or recurrent episode
First 61% (302) 71% (284) 65% (586)
Recurrent 39% (192) 29% (116) 35% (309)
Number of previous episodes
None 61% (302) 71% (284) 65% (586)
One 23% (114) 19% (76) 21% (191)
More than one 16% (78) 10% (40) 13% (118)
Treatment at baseline visit
Home treatment 17% (84) 19% (75) 18% (159)
Clinic treatment 49% (237) 52% (203) 50% (440)
Both 27% (131) 21% (83) 24% (214)
None 7% (32) 8% (30) 7% (62)
Sexual orientation (patient reported)
Heterosexual 83% (408) 98% (391) 90% (791)
Homosexual or bisexual 17% (84) 2% (8) 10% (92)
Attendance at GP clinic or other SH clinic for this episode of GW*
GP 38% (114) 47% (134) 42% (248)
Other SH clinic 16% (49) 15% (44) 16% (93)
None 51% (153) 42% (119) 46% (272)
*Participants reporting attendance with first episode only.
GP, general practitioner; GW, genital warts; SH, sexual health.
Table 3 Mean (95% CI) estimates of quality of life, duration of episode, cost of episode of care and QALY loss*
Source of estimate Men Women All
EQ-5D index Q 0.88 (0.86e0.90) 0.87 (0.83e0.90) 0.87 (0.85e0.89)
EQ-VAS Q 79 (77e80) 75 (71e78) 77 (76e79)
Disutilityy Q 0.043 (0.021e0.065) 0.063 (0.029e0.097) 0.056 (0.038e0.074)
Duration episode of care (days) CNR 35 (20e51) 37 (20e53) 36 (27e46)
Prescription/recovery time (days)z EO 39 (34e44) 37 (41e43) 36 (36e40)
Time to attendance (days) at clinic after noticing GWx Q 144 (112e174) 69 (48e90) 111 (88e135)
Mean QALY loss (days){ Q and CNR 6.6 (0.8e14.9) 6.5 (2.9e11.2) 6.6 (2.9e11.3)
Mean cost per episode of care (£), excluding STI screen CNR 80 (67e92) 109 (94e124) 94 (84e104)
Mean cost per episode of care (£), including STI screen** CNR 132 (120e144) 161 (146e176) 146 (136e157)
*Sampling weights applied.
yLoss of quality of life compared with UK population norms, as measured using the EQ-5D index.
zFor analysis of quality-adjusted life-year loss, additional time after the end of an episode of care was included, to allow for continued presences of genital warts after the last clinic visit. When
a prescription for home treatment was provided at the last visit, 28 days was added. When a clinic treatment was provided, 14e42 days was added as a reasonable recovery time (estimated
based on prescription duration and clinical opinion). A further 14 days were added at the end of the episode to allow quality of life to return to the population norm.
xn¼292, based on participants reporting attendance with first visit of first episode only. One patient who reported a warts episode of 23 years was excluded. Patients from the Homerton clinic
were also excluded, due to the large proportion of referrals from other centres. When participants provided a range the mid-point was taken to estimate the duration between a patient first
noticing their warts and completing the questionnaire. Sampling weights applied to mean estimates.
{Calculated by combining disutility estimates and duration between onset of warts and attendance at clinic from the questionnaire study with duration of an episode of care plus an allowance
for treatment and recovery.
**£52.12 per person, comprising laboratory processing costs of chlamydia, gonorrhoea, syphilis and HIV tests from a previous study.23
CNR, case note review; EO, expert opinion/literature; GW, genital warts; Q, questionnaire; QALY, quality-adjusted life-year; STI, sexually transmitted infection; VAS, visual analogue scale.
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QALY loss
The overall weighted mean loss of QALY associated with an
episode of genital warts for 16e64-year-olds in our base case
analysis was 0.018, equivalent to 6.6 days (95% CI 2.9 to 11.3) of
healthy life lost per episode (table 3).
In sensitivity analyses, the lower estimate scenario (using the
pre-episode and the episode of care durations only) resulted in
a mean QALY loss equivalent to 4.9 days (95% CI 1.6 to 9.5).
DISCUSSION
In this multicentre study we estimated that an episode of
genital warts is associated with a QALY loss equivalent to
6.6 days of healthy life lost. The cost of treatment per episode
of care in a sexual health clinic was estimated at £94 (exclu-
ding STI screen). Our results demonstrate that genital warts
present a substantial impact on the health service and the
individual.
This is the largest study of quality of life loss associated with
genital warts and provides the most detailed assessment of
current treatment costs in the UK. In contrast to some previous
studies, our results are based on responses from patients with
direct current experience of genital warts rather than expert
opinion or recall of previous episodes.28e30 Despite these
strengths, this study has some limitations. First, the question-
naire study may have been subject to participation bias. Data on
individuals who were not invited into the study, or who declined
an invitation to take part were not recorded accurately at all
sites. The participation rate and bias is therefore not known.
However, participants in the questionnaire and case note review
were comparable in terms of age and episode type, suggesting
the questionnaire participants were broadly representative of
clinic attendees with respect to these variables.
Second, it is not possible to conﬁrm a causal relationship
between the observed disutility and the presence of genital
warts. Our results support the hypothesis of a causal association
as most of the disutility was registered in the anxiety/depression
scale and the pain/discomfort scale, which is consistent with the
nature of genital warts. In addition, a trend for increased quality
of life after clearance was observed at follow-up, although this
was not signiﬁcant and the low response rate makes these
results difﬁcult to interpret.
Figure 1 Difference in EQ-5D index
score by age and sex.* *Sampling
weights applied.
Table 4 Characteristics of participants in the case note review
Male Female All
n[213 n[157 n[370
Age
Mean 30 25 28
Range (minemax) (16e77) (15e57) (15e77)
First or recurrent episode
First 66% (140) 73% (114) 69% (254)
Recurrent 34% (73) 27% (43) 31% (116)
Figure 2 Mean cost per episode of care (excluding STI screen) by
centre.* *Sampling weights applied. Error bars show 95% CI. Patients
receiving laser treatment at the Homerton are excluded from that
centre’s cost estimate, for purpose of the comparison of usual care.
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Our estimate of QALY loss is limited by the available infor-
mation on duration of warts and how long quality of life is
affected after the end of an episode of care. We did not collect
information about the duration with warts after a last visit as
part of this study, but it is feasible that concern over possible
future recurrence and future transmission to new partners13
would result in an ongoing disutility for a substantial period
after completion of an episode. Indeed, one previous study
suggested that quality of life was affected several months after
clearance.25 We applied assumptions about remaining impact on
quality of life based on treatment and clinical opinion. However,
our estimate may be a conservative one in the absence of further
data. Winer et al31 reported a median duration of warts of
5.9 months in a cohort of female university students. This is
comparable with our estimates of duration when the time
between noticing warts and attending clinic, and the duration of
the episode of care and allowances for treatment and recovery
times were combined (mean 174 days; 5.7 months).
We have previously reported cost per episode and quality of
life ﬁndings based on a similar study in a single sexual health
clinic in England.13 14 We improved on our previous method-
ology by collecting data from several centres, thus increasing the
precision and generalisability of our results. We also collected
information on the time with genital warts before attending the
clinic and data on the time taken for a visit to estimate staff
costs per visit more accurately.
Previous studies of treatment costs for genital warts have
reported a wide range of costs per episode, reﬂecting substantial
differences in study methodologies, healthcare settings and
treatment patterns. For example, in the UK, Brown et al29
reported a cost of £170 (2003 prices), but the authors used
clinician reports to determine treatment methods rather than
clinical data. Dee et al32 have reported a cost of £287 (2007
prices, Ireland), but this was based on a different costing
approach, whereby overall clinic costs were divided by the
proportion of clinic time required for warts. Langley et al33
reported a cost of £117 for men and £104 for women, based on
a case note review carried out in 2000. Costs per episode of £120
(2006 prices, Canada),34 £158 for men and £243 for women
(2009 prices, Australia),35 £276 (2002 prices, USA),36 £293 (2005
prices, France)37 and £287 (2007 prices, Ireland)32 have been
reported (exchange rates as at February 2011). Direct comparison
between these estimates should, however, be undertaken with
care. As shown by the variation between clinics, treatment costs
varied substantially by setting even within our study. Large
variation in treatment patterns has previously been observed33
and differences in terms of qualiﬁcation and grade of attending
clinical staff, time spent with the patient and the therapy of
choice all contribute to the variation seen in cost per episode of
care between centres. While we used local measurements of time
taken for a visit when possible, further local variation in costs of
overheads or the STI screen may not have been fully captured as
standard costings were applied.
Our estimates of disutility and QALY loss are at the lower end
of estimated ranges from two other studies using the EQ-5D
carried out in the UK (disutility among 18e25-year-olds of 0.05
for men and 0.11 for women)38 39 and Canada (disutility of
0.08e0.23 and QALY loss equivalent to 9e40 days of healthy life
lost per episode).40
Differences in the age distribution of the study populations
and different study methods offer possible explanations for the
lower estimates seen in our results.
As with our previous study, young women appeared to be the
most affected by having genital warts.13 This is in contrast to
16e19-year-old men, who appeared not to have signiﬁcant loss
of quality of life compared with population norms. This differ-
ence may be due to differences in the stigma associated with STI
between men and women; however, additional investigation
would be needed to investigate this difference further.
Our results are based on a detailed costing of time and
resources for a speciﬁc condition. Clinic payment in England is
based on agreed ‘tariff costs’ from commissioners to providers.
These payments (£133 per single-professional ﬁrst visit, £171 per
multi-professional ﬁrst visit, £101 per follow-up visit, 2010/11
genitourinary medicine tariffs)41 are not split according to
condition or treatment and they include direct overheads (util-
ities, management costs), which were not included in our esti-
mates. The tariff payments for an episode of genital warts
would therefore sum to more than our estimated costs.
We have presented information on quality of life losses
in patients with genital warts attending sexual health clinics,
and the resources used to treat them. To assess the total
population impact of genital warts, these data should be
considered together with the numbers of patients seen, and
care given, in general practice and cases referred to other
hospital care including surgery. It may be reasonable to assume
that the average disutility will be similar in patients attending
their general practitioner to those attending sexual health
clinics, but the disutility would be expected to be larger in
the small proportion of patients requiring other hospital-
based treatment. The cost of care is different in all three
settings.9 Future economic evaluations of HPV vaccination will
be able to utilise our results to compare the cost effectiveness of
bivalent versus quadrivalent HPV vaccination in the UK more
accurately.
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